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a  b  s  t  r  a  c  t
Pegylated interferon alpha (Peg IFN-) in combination with ribavirin is the backbone of
treatment in chronic hepatitis C (CHC). Cardiotoxicity due to interferon therapy is rare. The
most frequent cardiovascular complications are arrhythmias and ischemic manifestations.
Cardiomyopathy is extremely rare but can be life threatening. We  present the case of a 41-
year-old female patient with CHC in whom Peg IFN- induced dilated cardiomyopathy and
hypothyroidism.  Chest radiography showed an enlarged and globular cardiac silhouette and
pulmonary congestion. Echocardiography showed decreased left ventricular systolic func-
tion  with an ejection fraction of 32% and fractional shortening of 15%. Cardiomyopathy had
a  complete remission after cessation of antiviral therapy with short-term heart failure med-Thyroid  dysfunction ications  and supportive care. Then we review the current literature about interferon induced
cardiomyopathy in patients with HCV infection, as well as share our clinical experience in
diagnosing  and managing this rare complication.
did  induce dilated cardiomyopathy and hypothyroidism. Car-
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroduction
Hepatitis C virus (HCV) is a major public health problem,
involving approximately 170 million people worldwide.1 Pegy-
lated  interferon- (Peg IFN-) in combination with ribavirin
is  the backbone of treatment in patients with HCV infection
before  direct-acting antiviral agents (DAAs) became available,
and  still is the optimal choice for the majority of patients with
CHC.  Interferon- (IFN-)-induced thyroid dysfunction (TD)
has  been well documented, with an incidence ranging from
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Este é um artigo Open Access sob a licença10% to 27.7%.2–6 Cardiovascular complications caused by inter-
feron  consists mainly of arrhythmia, myocarditis, reversible
hypertension, ischemic heart disease, pericarditis and peri-
cardial  effusion.7–10 However, few cases of interferon-induced
cardiomyopathy have been reported.7,8,11–13 We herein report
a  patient with CHC in whom previous standard IFN- plus riba-
virin  had not induced severe complications, while Peg IFN-d Afﬁliated hospital, College of Medicine, Xi’an Jiaotong University,
diomyopathy had a complete remission after cessation of Peg
IFN-  and ribavirin. However, permanent thyroid hormone
replacement therapy is needed to treat hypothyroidism.
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Fig. 2 – Echocardiography showed decreased left ventricular
systolic function, including descending ejection fractionb r a z j i n f e c t d i s .
ase  presentation
 41-year-old woman  without history of heart disease was
dmitted  to our hospital with 2-week history of gradually
ncreasing dyspnea and fatigue in June 2008. She had a his-
ory  of rheumatoid arthritis for 10 years and was not receiving
ny  medications. Chronic hepatitis C had been diagnosed in
006, and HCV genotype was  2a. After initial therapy with
FN--2b  (3 MU,  3 times weekly) and ribavirin (800 mg/d) for
ix  months, HCV RNA was  undetectable by polymerase chain
eaction  at the end of treatment and six months follow-up.
n  January 2008, the patient consulted for CHC when she
egan  to experience generalized malaise and fatigue. The
atient’s  baseline chest radiograph showed normal lung ﬁelds
nd  no cardiomegaly, and an electrocardiogram was  normal.
aboratory  tests revealed an alanine aminotransferase (ALT)
evel  of 174 U/L (normal up to 40 U/L), aspartate aminotrans-
erase (AST) level of 123 U/L (normal up to 40 U/L), and positive
erology  for HCV. The HCV RNA level was  546,000 IU/mL. The
atient  refused liver biopsy prior to the second course of
nterferon  therapy. Combination therapy was  initiated with
eg  IFN--2a at the dose of 180 g per week in combina-
ion with ribavirin at the dose of 800 mg  daily. The patient
esponded well, her aminotransferase levels normalized, and
CV  RNA was  undetectable at week 4. After the twelfth week
f  treatment, the patient was  treated with levothyroxine for
ypothyroidism without discontinuation of antiviral therapy.
Physical  examination revealed blood pressure of
30/90 mmHg, heart rate of 122/min, a dilated jugular vein,
nd  an audible gallop rhythm and systolic ejection murmur.
here  was  mild peripheral edema. Chest radiography showed
n  enlarged and globular cardiac silhouette and pulmonary
ongestion without pleural effusion (Fig. 1). Serum free T3,
4,  total T3, T4 and thyroid stimulating hormone (TSH)
ere  within normal values with levothyroxine replacement
herapy at a dose of 50 g daily. Cardiac enzymes, liver
nzymes, erythrocyte sedimentation rate and C reactive
rotein were  normal. Antinuclear, antithyroperoxidase and
ntithyroglobulin antibodies were  positive. Rheumatoid
ig. 1 – Chest radiography showed an enlarged and
lobular cardiac silhouette and pulmonary congestion
ithout pleural effusion.and  fractional shortening.
factor and anti--myosin antibodies were absent. Coxsackie
virus,  Chlamydia pneumoniae and Mycoplasma pneumoniae
serology were negative. Echocardiography showed decreased
left  ventricular systolic function with an ejection fraction
(EF)  of 32% and fractional shortening (FS) of 15%, as well as
dilated  left ventricle with decreased wall motion of entire
left  ventricle (Fig. 2). Dilated cardiomyopathy and hypothy-
roidism secondary to Peg IFN-2a was  suspected. Therefore,
Peg  IFN- and ribavirin was  discontinued after 23 weeks of
treatment.  The patient was treated with Benazepril, Digoxin,
Furosemide, Metoprolol Succinate and Levothyroxine. Her
symptoms  improved in one week and she was  discharged
on  the same medications. A second echocardiogram three
months  later showed an EF of 47% with normal chambers, and
heart  failure medications were discontinued. She maintained
normal  aminotransferases and undetectable HCV RNA after
24  months of follow up. However, she needs permanent
thyroid hormone replacement therapy for hypothyroidism.
Discussion
Peg IFN- in combination with ribavirin was  the historical
backbone of treatment in patients with HCV infection in the
past  decade, and will still be the optimal choice for the major-
ity  of patients with CHC. As a result, the safety of combination
therapy is going to remain a major issue for patients with
CHC.  Although cardiovascular complications from IFN- are
scarce,  the growing number of patients receiving Peg IFN-
  therapy will undoubtedly lead to an increasing number
of  patients with cardiotoxicity. Out of these complications,
arrhythmia and ischemic heart disease are the predominant
types, followed by myocarditis and reversible hypertension,
while cardiomyopathy is rare.7,8 To the best of our knowledge,
only  six cases of cardiomyopathy associated with IFN- treat-
ment  for chronic hepatitis C has been described to date in
English  literature, including our case.7,12,13 The clinical data
of  the six cases are shown in Table 1.
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Table 1 – Case reports of cardiomyopathy associated with interferon- therapy for HCV in the literature.
Authors/years Age/sex Administered Duration of
IFN therapy
Medical history Other toxicity Treatment Outcome
Teragawa et al.8 59/F Natural IFN-a 19 wk Hypertension N/A D + S Resolved
57/F Recombinant IFN--2ba 6 wk None N/A D + S Resolved
Condat et al.12 45/M Peg IFN--2b 24 wk Palpitations Pleural effusion D + S Death
Choy-Shan et al.13 49/M Peg IFN- 36 wk Hypertension/DM None D + S + BK No resolved
64/M Peg IFN- 48 wk DM None D + S N/A
Current case 41/F Peg IFN--2a 23 wk RA Hypothyroidism D + S Resolved
Peg IFN-, pegylated interferon alpha; DM, diabetes mellitus; RA, rheumatoid arthritis; D, discontinuation pegylated interferon alpha; S, sup-
portive care; BK, biventricular pacemaker; N/A, data not available.
 weeka The IFN- dose is 6 MU daily for the ﬁrst 2 weeks and 6 MU 3 times
The present patient was  the ﬁrst case to develop cardiomy-
opathy and hypothyroidism after standard of care antiviral
treatment for HCV infection. In this case, Peg IFN- may
have  been responsible for the onset of cardiomyopathy. Argu-
ments  in support of a correlation between Peg IFN- and
cardiomyopathy include the following aspects: all other pos-
sible  infectious and drugs or systemic causes were ruled
out;  cardiotoxicity was  present during Peg IFN- treatment;
cardiotoxicity regression after drug withdrawal; absence of
any  previous heart disease history and speciﬁc investigations
before treatment excluding a pre-existing cardiomyopathy,
and the symptoms and the results of the various investiga-
tions  carried out in the context of the dilated cardiomyopathy.
We  used the causal criteria from the World Health Organiza-
tion  to show the probability of adverse drug reaction.14
The mechanism behind IFN- induced cardiotoxicity was
not  yet clariﬁed. In reported cases, the dose of standard IFN-
  was  always higher than three million units, three times
a  week, and in the majority of cases very high doses were
used.7,8,10,11 Cardiomyopathy associated with standard IFN-
treatment for CHC is extremely rare, maybe due to the lower
doses.  The only two reported cases were administration of
IFN-  at a dose of six million units daily for the ﬁrst two
weeks and six million units three times weekly thereafter.8
Our patient present cardiomyopathy during Peg IFN- rather
than  standard IFN- therapy. Whatever the mechanism, it is
conceivable  that pegylated interferon provides higher levels
of  interferon plasma concentration in a continuous fashion
because  of prolonged half-life, and thus could bear a higher
risk  of cardiomyopathy. On the other hand, there are no
described  predisposing factors for interferon cardiotoxicity.
Studies have shown that combination therapy with Peg IFN-
and  ribavirin does not cause a signiﬁcant deterioration in car-
diac  function in patients without cardiac disease15 and may  be
safely  offered to carefully selected chronic hepatitis C patients
with  coexisting, clinically signiﬁcant heart disease,16 indicat-
ing  that the diverse genetic predisposition of the individuals
may  substantially contribute to cardiotoxicity.
Cardiomyopathy induced by standard IFN- was  always
reversible when there was  no concomitant factor.7,8,11 Con-
versely,  Peg IFN- related cardiomyopathy showed a poor
prognosis.12,13 Although our case had complete resolution of
the  cardiomyopathy, one case died due to cardiogenic shock12
and another case had irreversible ventricular dysfunction andly thereafter.
remains symptomatic despite maximal medical therapy and
implant  of a biventricular pacemaker.13
TD is a relatively common adverse reaction to IFN- based
therapy  and it also represents an extra-hepatic manifestation
of  HCV infection.3,5 Studies have shown that the incidence of
TD  associated with IFN- therapy differs markedly between
racial  and ethnic groups and ﬁbrosis stages, with an incidence
ranging  from 10% to 27.7%.2–6 The majority of TD is hypothy-
roidism, and more  than half of them return spontaneously to
normal after cessation of antiviral therapy.3–6 However, a few
patients,  as well as our case, need permanent thyroid hormone
replacement therapy.3–6 Fortunately, it does not always neces-
sitate  alteration or discontinuation of therapy due to TD,2–6,17
and it also does not impact the response to combination ther-
apy  with interferon and ribavirin.3,17
Conclusion
We report a patient without any history of cardiac disease
who  developed dilated cardiomyopathy and hypothyroidism
after Peg IFN- plus ribavirin treatment. Cardiomyopathy is an
exceptional but unanticipated complication of antiviral ther-
apy  for HCV infection. It may  be associated with the diverse
genetic  predisposition of individuals. Prompt discontinuation
of  HCV medication is mandatory, and short-term heart fail-
ure  medications together with supportive care are essential.
Clinicians should be aware of this potentially cardiovascular
complication and the possible acuity of its onset. We suggest
that  periodic monitoring of the cardiac function is neces-
sary,  especially for symptomatic patients, to detect early toxic
effects  during interferon administration.
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